Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAmeriHealth VIP Care IB-Stim Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAmeriHealth Caritas VIP CarePolicy CCP.1482

    Auricular Stimulation for Abdominal Pain From Irritable Bowel Syndrome

    Customize your policy alerts

    Sign up for amerihealth_caritas_vip_care Policy CCP.1482 alerts

    Get alerted when Policy CCP.1482 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage determinations for percutaneous electrical nerve field stimulation, including IB-Stim, for functional abdominal pain related to irritable bowel syndrome; coverage may be medically necessary for members ages 4 through 18 who have not achieved adequate relief with gut-brain psychotherapies and other conservative measures.

    Policy Summary
    PayerAmeriHealth Caritas VIP Care
    PolicyAuricular Stimulation for Abdominal Pain From Irritable Bowel Syndrome
    Policy CodePolicy CCP.1482
    Change TypeCoverage changed to medically necessary for eligible children
    Effective DateApril 1, 2021
    Last ReviewMar 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionDocument the member’s age, IBS-related functional abdominal pain, inadequate relief from conservative measures, and contraindication screening.
    SourceLink
    POLICY UPDATE CHANGES

    In March 2026, coverage changed from investigational to medically necessary for auricular stimulation in children with refractory pain from irritable bowel syndrome.

    Policy references were updated annually from March 2022 through March 2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4–18Age range for covered members
    3Listed contraindications
    120 hr/weekFDA-described device use
    59% vs 26%Pain reduction with IB-Stim vs sham
    81% vs 26%Overall symptom response vs sham

    Coverage Criteria

    Initial therapy

    Covered when ALL of the following are met:

    Covered pediatric use

    • Age: The member is age 4 through 18 years.4-18 years
    • Condition: The member has functional abdominal pain related to irritable bowel syndrome.
    • Inadequate response to conservative care: The member has not achieved adequate pain relief with gut-brain psychotherapies and other conservative measures.

      Conservative measures may include standard-of-care treatment customized to symptoms and triggers.

    Auricular stimulation is contraindicated for members with a cardiac pacemaker, hemophilia, or psoriasis vulgaris. For members with a cardiac pacemaker, no clinical data are available.

    Coverage is limited to the supported pediatric population. Adult use is excluded because safety and efficacy have been studied inadequately, the evidence remains very limited, and adult guideline support is lacking.

    Related Codes

    Related codesCPT
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation

    Provider Documentation and Decision Points

    Documentation Required

    Clinical Eligibility Documentation

    Document that the member is 4–18 years old and has functional abdominal pain related to irritable bowel syndrome. The record must also show considerable difficulty achieving adequate pain relief with gut-brain psychotherapies and other conservative measures.

    • Member age: 4–18 years.
    • Diagnosis: functional abdominal pain related to irritable bowel syndrome.
    • Treatment response: inadequate or insufficient pain relief despite gut-brain psychotherapies and other conservative measures.
    Documentation Required

    Contraindication Screening Required

    Before requesting or providing auricular stimulation, document assessment for the device-specific contraindications listed below. Coverage may be denied when any contraindication is present.

    • Cardiac pacemaker, because clinical data are unavailable.
    • Hemophilia.

    Clinical Background

    Auricular stimulation, also called percutaneous electrical nerve field stimulation, is a non-implanted neuromodulatory treatment used for functional abdominal pain and functional dyspepsia associated with irritable bowel syndrome. The FDA-cleared IB-Stim device applies low-voltage electrical current to cranial and occipital nerve fields around the ear and is used with other therapies. Evidence supports short-term safety and efficacy in children and adolescents, while adult evidence remains limited and lacks guideline support.

    Treatment Definitions

    IB-Stim
    Device classClass II, non-implanted percutaneous nerve stimulator
    Electrical outputApplies low-voltage electrical current
    Nerve targetsBranches of cranial nerves V, VII, IX, and X, and the occipital nerve field around the ear
    FDA-described useUsed with other therapies for functional abdominal pain and functional dyspepsia associated with irritable bowel syndrome
    Intended treatment schedule120 hours per week for up to four consecutive weeks
    Auricular stimulation
    Definition
    Policy Summary
    PayerAmeriHealth Caritas VIP Care
    PolicyAuricular Stimulation for Abdominal Pain From Irritable Bowel Syndrome
    Policy CodePolicy CCP.1482
    Change TypeCoverage changed to medically necessary for eligible children
    Effective DateApril 1, 2021
    Last ReviewMar 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionDocument the member’s age, IBS-related functional abdominal pain, inadequate relief from conservative measures, and contraindication screening.
    SourceLink
    On This Page
    Coverage CriteriaRelated CodesProvider Documentation and Decision PointsClinical BackgroundTreatment Definitions
  1. Psoriasis vulgaris.
    2. Denial Risk

    Coverage Denial: Eligibility Criteria Not Met

    Auricular stimulation is medically necessary under this policy only for members age 4–18 years with functional abdominal pain related to irritable bowel syndrome who have not achieved adequate pain relief with gut-brain psychotherapies and other conservative measures. Coverage may be denied when the age requirement or conservative-treatment and response criteria are not met.

    • Do not submit for members younger than 4 or older than 18 years.
    • Document failure to achieve adequate pain relief with gut-brain psychotherapies and other conservative measures.
    Denial Risk

    Denial Risk: Contraindications

    Screen for and document the absence of contraindications before treatment. Auricular stimulation may be denied or considered unsafe when the member has a cardiac pacemaker, hemophilia, or psoriasis vulgaris.

    • Cardiac pacemaker.
    • Hemophilia.
    • Psoriasis vulgaris.
    Denial Risk

    Denial Risk: Insufficient Adult Evidence

    Evidence supporting auricular stimulation is insufficient for adults. The policy-supported medically necessary indication is limited to children and adolescents ages 4–18 years; adult requests carry a denial risk because safety and efficacy have been inadequately studied and lack guideline support.

    • Adult pilot evidence was limited to a small randomized study with 7 IB-Stim participants and 8 sham participants.
    • No established adult guideline support was identified.
    Percutaneous electrical nerve field stimulation delivered through auricular stimulation
    Clinical useTreats functional abdominal pain related to irritable bowel syndrome
    Treatment approachA non-implanted neuromodulatory treatment used with other therapies
    Supported populationMembers ages 4 through 18 years who have not achieved adequate pain relief with gut-brain psychotherapies and other conservative measures